KR Choksey has recommended accumulate rating on Cadila Healthcare with a target price of Rs 436 in its research report dated February 09, 2018.
KR Choksey's research report on Cadila Healthcare
Cadila posted revenue of INR 32,596 Mn with growth of 37.9% Y-o-Y and 48% Q-o-Q. The company had 180 days exclusivity of gLialda which has an estimated market size of USD 1.1 mn. Cadila has also launched Tamiflu in the quarter which boosted the US business of the company. The company expects 4% price erosion in its base portfolio which will be subdued by new launches.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.